法定代表人：戴斯觉 主管会计工作负责人：王延军 会计机构负责人： 温文秀 保龄宝生物股份有限公司2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会计 | 2023年期初占 | 2023年1-6月占用 累计发生金额 | 2023年1-6月占用资 | 2023年1-6月偿 | 2023年6月末占 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 科目 | 用资金余额 | （不含利息） | 金的利息(如有) | 还累计发生金额 | 用资金余额 | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际 控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | ...

股票代码：002286 股票简称：保龄宝 公告编号：2023-040 保龄宝生物股份有限公司 第五届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 保龄宝生物股份有限公司（以下简称"公司"）关于召开第五届监事会第十 九次会议的通知于 2023 年 08 月 13 日以电子邮件的方式发出，会议于 2023 年 8 月 24 日以通讯表决的方式召开。会议应参加表决的监事 3 人，实际表决的监事 3 人。会议的召开符合有关法律、行政法规、部门规章、规范性文件和公司章程 的规定。 二、会议审议情况 1、会议以3票同意、0 票反对、0 票弃权，审议通过《2023年半年度报告全 文及摘要》； 并出具审核意见如下： 1、公司《2023年半年度报告》及摘要的编制和审议程序符合法律、法规、 《公司章程》和公司内部管理制度的各项规定； 2、公司《2023年半年度报告》及摘要的内容和格式符合中国证监会和深圳 证券交易所的各项规定，内容真实、准确、完整，所包含的信息从各个方面真实 地反映出公司2023年上半年的经营管理和财务状况等事项，不 ...

证券代码：002286 证券简称：保龄宝 公告编号：2023-039 保龄宝生物股份有限公司 第五届董事会第二十二次会议决议公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 录、误导性陈述或者重大遗漏。 一、会议召开情况 保龄宝生物股份有限公司（以下简称"保龄宝"或"公司"）关于召开第五 届董事会第二十二次会议的通知于 2023 年 8 月 13 日以电子邮件的方式发出，会 议于 2023 年 8 月 24 日以通讯表决的方式召开。会议应参加表决的董事 8 人，实 际表决的董事 8 人。会议的召开符合《公司法》和《公司章程》等法规的规定。 二、会议审议情况 会议以 8 票同意、0 票反对，0 票弃权，审议通过了《2023 年半年度报告全 文及摘要》。 根据《公司法》、《证券法》、《公司章程》及其他有关规定，经董事会认真审 核，认为《公司 2023 年半年度报告》及其摘要的编制和审核程序符合法律法规 及相关监管规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在 任何虚假记载、误导性陈述或者重大遗漏。 详情见与本决议公告同日发布在指定信息披露媒体上的《保龄宝生物股份有 限公司 20 ...

证券代码：002286 证券简称：保龄宝 公告编号：2023-038 保龄宝生物股份有限公司 关于公司监事辞职的公告 2023 年 08 月 08 日 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 保龄宝生物股份有限公司（简称"公司"）监事会于 2023 年 08 月 07 日收 到公司监事周皓先生递交的书面辞职报告，周皓先生因个人原因向公司辞去监事 职务，辞职后将不再在公司及子公司担任任何职务。 截止本公告披露日，周皓先生未持有公司股票，不存在应当履行而未履行的 承诺事项。根据《公司法》、《公司章程》和《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》的有关规定，周皓先生的辞职将导致 公司监事会成员低于法定最低人数，其辞职申请将在公司股东大会选举产生新任 监事后生效。在此期间，周皓先生将继续履行监事职责。周皓先生辞去监事职务 不影响公司正常生产经营。 公司监事会对周皓先生担任公司监事期间为公司所作的贡献表示感谢！ 特此公告。 保龄宝生物股份有限公司 监事会 ...

证券代码： 002286 证券简称：保龄宝 保龄宝生物股份有限公司投资者关系活动记录表 | --- | --- | |----------|----------------------------------------------------------------------------| | | 编号：2023-002 | | 投资者关 | □ 分析师会议 | | 系活动类 | □ 业绩说明会 | | 别 | □ 路演活动 | | | □ 其他 | | 参与单位 | 天风证券股份有限公司（林逸丹、盖元萁、施嘉鸿）；C.C.F. Group 创智资本（陈 | | 名称及人 | 哲）；北京诚盛投资管理有限公司（胡蓉）；北京金百镕投资管理有限公司（张 | | 员姓名 | 甲）；成都万象华成投资管理有限公司（向柯舟）；诚通基金管理有限公司（刘 | | | 博）；东方基金管理有限责任公司（郭绍珺）；东方睿石投资管理有限公司（唐 | | | 谷军）；东吴证券股份有限公司（自营）（滕越）；东证融汇资产管理有限公司 | | | （卢诗凝）；敦和资产管理有限公司（江源）；方正证券股份有限公司（刘斐）； | | | 富荣基 ...

保龄宝生物股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 10 日 (周三) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理戴斯觉 | | 员姓名 | 2、独立董事黄永强 | | | 3、副总经理、财务总监王延军 | | | 4、副总经理、董事会秘书张国刚 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、公司未来三年的发展规划是什么？ | | | 尊敬的投资者您好，未来，公司聚焦点更多会是在推动下游 | | | 食品饮料客户使用天然 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year growth of 15%[19]. - The company's operating revenue for 2022 was ¥2,712,745,317.35, a decrease of 1.89% compared to ¥2,764,976,972.69 in 2021[20]. - Net profit attributable to shareholders decreased by 33.94% to ¥133,168,839.10 in 2022 from ¥201,579,400.15 in 2021[20]. - Basic earnings per share fell by 33.33% to ¥0.36 in 2022, compared to ¥0.54 in 2021[20]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing ¥22,591,028.16, down from ¥48,028,304.48 in the second quarter[24]. - The company achieved a total revenue of 2.713 billion yuan in 2022, a year-on-year decrease of 1.89%[103]. - The net profit attributable to shareholders was 133.17 million yuan, down 33.94% compared to the previous year, primarily due to a supply-demand imbalance in competitive products like erythritol[103]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[185]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, based on a total of 371,812,900 shares[5]. - The company has not proposed any stock bonus or capital increase from reserves, focusing solely on cash dividends[5]. - The company's annual shareholder meeting had a participation rate of 32.26% on May 20, 2022[173]. - The first temporary shareholder meeting in 2022 had a participation rate of 20.31% on July 25, 2022[173]. - The second temporary shareholder meeting in 2022 had a participation rate of 32.15% on November 3, 2022[173]. Governance and Management - The company emphasizes the importance of accurate and complete financial reporting, with key personnel affirming the integrity of the annual report[4]. - The board of directors has fully attended the meeting to review the annual report, ensuring governance and oversight[5]. - The company’s governance structure complies with legal regulations, with no significant discrepancies noted[166]. - The company operates independently in business, personnel, assets, and finance, ensuring no interference from the controlling shareholder[167]. - The company experienced a change in management with the resignation of General Manager Wu Huaixiang on September 30, 2022, due to personal reasons[176]. - Xu Bei was elected as the new Supervisory Board Chairwoman on December 12, 2022, following the resignation of Xiong Shuqin[177]. - The management team is composed of experienced professionals with backgrounds in finance, engineering, and food science, enhancing the company's strategic capabilities[178]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation and product development[19]. - The company has developed over 90 functional sugar products, expanding from a single product to a full range of offerings over 20 years of innovation[92]. - The company’s R&D investment amounted to ¥101,574,654.50 in 2022, representing a 0.96% increase from ¥100,613,062.55 in 2021, and accounted for 3.74% of total revenue[119]. - The company is developing new products such as D-alloheptulose and high-value lactose derivatives to meet market demands[116]. - The company is committed to enhancing its research and development capabilities in functional sugars to maintain its competitive edge in the market[154]. Market Expansion and Strategy - The company is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 5% from this region by 2024[19]. - The company plans to launch three new products in 2023, focusing on health supplements and functional foods, aiming for a 10% increase in market share[19]. - The company plans to continue expanding its investor outreach efforts to enhance market understanding and engagement[157]. - The company is planning to expand its market presence in Southeast Asia, targeting a 25% market share within the next three years[185]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's product portfolio and increase market competitiveness[185]. Financial Health and Risks - The company has outlined potential risks in its future business operations, which investors are advised to consider[5]. - The net cash flow from operating activities dropped significantly by 85.06% to ¥30,821,782.60 in 2022, down from ¥206,267,702.76 in 2021[20]. - The company recognized non-recurring gains of ¥9,093,764.51 in 2022, compared to ¥37,209,655.04 in 2021[26]. - The company is exploring partnerships with international firms to enhance its global distribution network[160]. - The company recognizes risks associated with raw material price fluctuations, particularly for corn and sugar, and plans to mitigate these through futures hedging and improved production processes[152]. Product Development and Innovation - The company operates in the functional sugar industry, focusing on enzyme engineering and fermentation technology, with products widely used in health foods and pharmaceuticals[31]. - The company has achieved industrial production of various functional oligosaccharides, including isomalt oligosaccharides, fructooligosaccharides, galactooligosaccharides, and xylooligosaccharides, which are primarily used in functional foods, nutritional supplements, and the feed industry[35]. - The company has successfully developed and industrialized new products such as allulose and specific prebiotics, enhancing its functional sugar product system[81]. - The company aims to enhance its core product competitiveness through the industrialization of new sweetener products[116]. - The company is actively pursuing digital factory construction to enhance production transparency, traceability, and efficiency, thereby improving product quality[151]. Investor Relations - The company conducted multiple investor communications, including a site visit and conference calls, to discuss business conditions and industry developments[156]. - The company emphasized the importance of investor relations and transparency in its communications strategy[156]. - The company is dedicated to maintaining a strong relationship with its investors through regular updates and strategic discussions[156]. - The company highlighted its commitment to market expansion and potential mergers and acquisitions as part of its growth strategy[157]. Sustainability and Corporate Responsibility - The company has received multiple awards for its sustainability and quality, including recognition from Coca-Cola and other major partners[98]. - The company is positioned to benefit from national health policies aimed at improving public health and promoting healthy lifestyles[78]. - The company has established independent production and office locations, with no mixed operations with other entities[172].

Financial Performance - In Q1 2023, the company's revenue was CNY 610.27 million, a decrease of approximately 7.22% year-on-year[4] - The net profit attributable to shareholders was CNY 17.05 million, down about 60.09% compared to the same period last year[4] - The company reported a 67.51% decrease in net profit after deducting non-recurring gains and losses, amounting to CNY 12.78 million[7] - Total operating revenue for Q1 2023 was CNY 610.27 million, a decrease of 7.15% from CNY 657.77 million in Q1 2022[19] - Net profit attributable to the parent company for Q1 2023 was CNY 17.05 million, a decline of 60.14% compared to CNY 42.72 million in Q1 2022[21] - Earnings per share for Q1 2023 were CNY 0.05, down from CNY 0.11 in Q1 2022[21] - The company reported a comprehensive income total of CNY 32.62 million for Q1 2023, compared to CNY 29.78 million in Q1 2022[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 1.12 million, a 100.83% increase from a negative cash flow of CNY 136.11 million in the previous year[7] - The company's cash and cash equivalents as of March 31, 2023, amount to ¥332,200,073.90, down from ¥375,948,557.69 at the beginning of the year[17] - The net cash flow from operating activities for Q1 2023 was ¥1,123,765.76, a significant improvement compared to a net outflow of ¥136,105,401.07 in Q1 2022[24] - Total cash inflow from operating activities was ¥669,049,904.66, while cash outflow was ¥667,926,138.90, resulting in a net cash flow of ¥1,123,765.76[24] - The total net increase in cash and cash equivalents was -¥55,748,483.79, compared to a decrease of -¥60,824,389.74 in the same period last year[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3.00 billion, a slight decrease of 0.09% from the end of the previous year[7] - The company's total liabilities decreased to CNY 965.17 million in Q1 2023 from CNY 1,001.79 million in Q1 2022[20] - Non-current liabilities totaled CNY 205.71 million in Q1 2023, down from CNY 242.59 million in Q1 2022[20] - The company's total equity increased to CNY 2,038.36 million in Q1 2023 from CNY 2,004.34 million in Q1 2022[20] - Total assets amount to ¥3,003,533,045.76, slightly down from ¥3,006,135,458.00 at the beginning of the year[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 39,447[12] - The top shareholder, Beijing Yongyu Investment Management Co., Ltd., holds 12.71% of shares, totaling 47,273,390 shares, with 8,000,000 shares frozen[12] - The second-largest shareholder, Ningbo Baopu Futong Asset Management Center, holds 10.26% of shares, totaling 38,139,244 shares[12] Operational Insights - The company plans to focus on the development of low-sugar and sugar substitute products, capitalizing on the growing market demand[5] - The domestic probiotic industry is entering a rapid expansion phase, presenting new opportunities for the company[5] - The company aims to leverage its brand, quality, and customer resources to develop differentiated products and integrated application solutions[5] - The company anticipates strong growth in market demand for erythritol products as competition improves and consumption continues to recover[5] - The company experienced a significant increase in management expenses, rising by 50.95% to CNY 28.74 million due to increased parking fees[11] Inventory and Receivables - Accounts receivable increased to ¥239,415,254.17 from ¥234,259,204.26, indicating a slight growth[17] - Inventory as of March 31, 2023, is ¥377,959,782.98, up from ¥335,390,465.63 at the beginning of the year[17] Research and Development - The company reported a decrease in research and development expenses to CNY 1.79 million in Q1 2023 from CNY 1.88 million in Q1 2022[20] Offering and Financing - The company is in the process of a non-public offering of A-shares, fully subscribed by its controlling shareholder, Beijing Yongyu, and its affiliates[14] Tax and Employee Payments - The company received tax refunds amounting to ¥17,847,131.34 during the quarter[24] - Payments to employees totaled ¥36,049,106.06, down from ¥43,968,041.63 in Q1 2022[24] Audit Status - The report for Q1 2023 was not audited[26]

本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002286 证券简称：保龄宝 公告编号：2023-009 保龄宝生物股份有限公司 关于举行2022年度业绩说明会的公告 （问题征集专题页面二维码，扫码自动匹配移动端） 特此公告。 保龄宝生物股份有限公司董事会 2023 年 4 月 27 日 保龄宝生物股份有限公司（以下简称"公司"） 定于 2023 年 5 月 10 日（周 三）下午 3:00-5:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登录全景网"投资者关系互动平台" （http://ir.p5w.net） 参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长、总经理戴斯觉先生；独立 董事黄永强先生；副总经理、财务总监王延军先生；副总经理、董事会秘书张国 刚先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 9 日（星期二）17：00 前访问 ht ...

Group 1: Company Overview and Performance - Baolingbao aims to solidify its position as a leading enterprise in the probiotics sector through customer value-centric business models [2] - The company is focusing on the health industry, which is supported by national policies and market demand, indicating a broad development prospect [2] Group 2: Animal Nutrition Business Development - The company successfully expanded the application of oligomaltose as a new feed additive for weaned piglets, enhancing growth rates and feed efficiency [3] - The new feed additive reduces the need for preventive antibiotics, promoting safer livestock products [3] Group 3: Financial Performance and Challenges - The company faced a temporary increase in corn starch prices, leading to a decline in gross profit margin [4] - Strategies to mitigate cost pressures include strategic corn reserves, product price adjustments, and production cost reductions [4] Group 4: Terminal Products and Market Expansion - Sales of terminal products are performing well, with increasing brand recognition and rapid growth in e-commerce sales [4] - The management is promoting a comprehensive business development model to establish itself as "China's leading brand in gut health" [4] Group 5: Fructose Syrup Business Situation - Financial data indicates a decline in fructose business due to historically low sugar prices, which have affected demand [5] - Despite this, there is significant future market potential for fructose syrup in China, which is expected to provide stable profits [5] Group 6: Competitive Advantages - Baolingbao is the first domestic company to industrialize the production of oligosaccharides, establishing unmatched advantages in market influence, brand recognition, and production capacity [5] - The company's products are characterized by low sugar, low calories, high fiber, and health benefits, aligning with current market consumption trends [5] Group 7: International Business Development - The company is actively pursuing international certifications, including KOSHER and organic product certifications, to expand its export range [5] - The export business has seen significant growth due to these efforts [5]